A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II α

被引:11
|
作者
Jensen, LH
Renodon-Cornière, A
Nitiss, KC
Hill, BT
Nitiss, JL
Jensen, PB
Sehested, M
机构
[1] Rigshosp, Lab Ctr, Dept Pathol, DK-2100 Copenhagen, Denmark
[2] Rigshosp, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark
[3] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38018 USA
[4] Ctr Rech Pierre Fabre, Div Cancerol, F-81100 Castres, France
关键词
topoisomerase II; epipodophyllotoxin; chemotherapy; DNA damage; surface plasmon resonance; mutation;
D O I
10.1016/S0006-2952(03)00342-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
F 11782 is a novel epipodophyllotoxin that targets eukaryotic topoisomerases and inhibits enzyme binding to DNA. While F 11782 has not been found to stabilize either topoisomerase I or topoisomerase II covalent complexes, drug treatment appears to result in DNA damage. F 11782 has also been shown to inhibit the DNA nucleotide excision repair (NER) pathway. Bisdioxopiperazine-resistant small cell lung cancer (SCLC) OC-NYH/Y165S and Chinese hamster ovary (CHO) CHO/159-1 cells having functional Y49F and Y165S mutations in the topoisomerase II alpha isoform were both resistant to F 11782. The catalytic activity of purified human Y50F and Y165S mutant topoisomerase 11 a (Y50F in the human protein corresponds to Y49F in the CHO protein) was likewise resistant to the inhibitory action of F 11782. F11782 was also found to induce a non-covalent salt-stable complex of human topoisomerase II with DNA that was ATP-independent. F 11782 thus displays a dual mechanism of action on human topoisomerase II alpha, reducing its affinity for DNA while also stabilizing the protein bound in the form of a salt-stable complex. Our results suggest that topoisomerase II alpha is a target of F 11782 in vivo, and that F 11782 may act as a novel topoisomerase II poison. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:623 / 631
页数:9
相关论文
共 50 条
  • [1] F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action
    Perrin, D
    van Hille, B
    Barret, JM
    Kruczynski, A
    Etiévant, C
    Imbert, T
    Hill, BT
    BIOCHEMICAL PHARMACOLOGY, 2000, 59 (07) : 807 - 819
  • [2] Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents
    Barret, JM
    Kruczynski, A
    Etiévant, C
    Hill, BT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (06) : 479 - 486
  • [3] Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents
    Jean-Marc Barret
    Anna Kruczynski
    Chantal Etiévant
    Bridget T. Hill
    Cancer Chemotherapy and Pharmacology, 2002, 49 : 479 - 486
  • [4] F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103
    Etiévant, C
    Kruczynski, A
    Barret, JM
    Perrin, D
    van Hille, B
    Guminski, Y
    Hill, BT
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (02) : 101 - 113
  • [5] F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103
    Chantal Etiévant
    Anna Kruczynski
    Jean-Marc Barret
    Dominique Perrin
    Benoît van Hille
    Yves Guminski
    Bridget T. Hill
    Cancer Chemotherapy and Pharmacology, 2000, 46 : 101 - 113
  • [6] F11782, a novel dual topoisomerase I and II inhibitor exhibits significant in vitro activity against fresh cells from haematological malignancies
    Sargent, JM
    Elgie, AW
    Williamson, CJ
    Taylor, C
    Hill, BT
    LEUKEMIA, 2001, 15 (03) : 507 - 507
  • [7] A Natural Anticancer Agent Thaspine Targets Human Topoisomerase IB
    Castelli, Silvia
    Katkar, Prafulla
    Vassallo, Oscar
    Falconi, Mattia
    Linder, Stig
    Desideri, Alessandro
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2013, 13 (02) : 356 - 363
  • [8] Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents
    Cincinelli, Raffaella
    Musso, Loana
    Artali, Roberto
    Guglielmi, Mario B.
    La Porta, Ilaria
    Melito, Carmela
    Colelli, Fabiana
    Cardile, Francesco
    Signorino, Giacomo
    Fucci, Alessandra
    Frusciante, Martina
    Pisano, Claudio
    Dallavalle, Sabrina
    PLOS ONE, 2018, 13 (10):
  • [9] Novel angular benzophenazines: Dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents
    Vicker, N
    Burgess, L
    Chuckowree, IS
    Dodd, R
    Folkes, AJ
    Hardick, DJ
    Hancox, TC
    Miller, W
    Milton, J
    Sohal, S
    Wang, SM
    Wren, SP
    Charlton, PA
    Dangerfield, W
    Liddle, C
    Mistry, P
    Stewart, AJ
    Denny, WA
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (03) : 721 - 739
  • [10] AD-O53.2-novel biological anticancer therapeutic agent with a dual mechanism of action
    Poleszak, K.
    Pieczykolan, J.
    Pawlak, S.
    Zerek, B.
    Rozga, P.
    Teska-Kaminska, M.
    Galazka, M.
    Szymanik, M.
    Jaworski, A.
    Pieczykolan, A.
    Bukato, K.
    Strozek, W.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 169 - 169